Report cover image

US General Anesthesia Drugs Market Size- By Route of Administration, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

Publisher SPER Market Research Pvt. Ltd.
Published Jan 20, 2024
Length 106 Pages
SKU # SPER19034004

Description

US General Anesthesia Drugs Market Size- By Route of Administration, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033


US General Anesthesia Drugs Market Introduction and Overview

According to SPER market research, ‘US General Anesthesia Drugs Market Size-By Route of Administration, By End User – Regional Outlook, Competitive Strategies and Segment Forecast to 2033’state that the US General Anesthesia Drugs Market is predicted to reach USD 3.18 Billion by 2033 with a CAGR of 3.6%.

General Anaesthesia in the US A class of medications called drugs is used to cause anaesthesia. Generally speaking, they fall into three categories: sedatives, which help patients rest; neuromuscular blocking drugs, which paralyse muscles; and general anaesthetics, which cause anaesthesia.

Due to the burden on healthcare systems and the cancellation or postponement of elective surgeries, the COVID-19 pandemic is predicted to have a negative effect on the market for general anaesthesia drugs. Increased risks of post-operative complications and mortality were noted in a February 2023 Review for Medical and Pharmacological Sciences article for patients with recent or continuing COVID-19 infections. Anaesthesia use is made more difficult by possible drug interactions and the impossibility of a safe gap between COVID-19 therapy and surgery.

Scope of the Report:

Report Metric Details
Market size available for years 2019-2033
Base year considered 2022
Forecast period 2023-2033
Segments covered By Route of Administration, By End User
Regions covered
Central Region, North Region, South Region

Companies Covered

Abbott Laboratories, AbbVie, Akorn, AstraZeneca plc, Baxter International Inc., Gilead Sciences, Inc, Heritage Pharmaceuticals Inc., Novartis AG, Par Pharmaceutical, Pfizer Inc., Others

US General Anesthesia Drugs Market Key Segments Covered

By End User:Based on the End User, US General Anesthesia Drugs Market is segmented as; Ambulatory Surgery Centres, Hospitals.

By Region:This research also includes data for Central Region, North Region, South Region.

Table of Contents

106 Pages
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the US General Anesthesia Drugs Market
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. US General Anesthesia Drugs Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in US General Anesthesia Drugs Market
7. US General Anesthesia Drugs Market, By Route of Administration (USD Million)
7.1. US General Anesthesia Drugs Market Value Share and Forecast, By Route of Administration, 2023-2033
7.2. Inhalational
7.2.1. Desflurane
7.2.2. Isoflurane
7.2.3. Nitrous Oxide
7.2.4. Sevoflurane
7.3. Intravenous
7.3.1. Benzodiazepines
7.3.2. Etomidate
7.3.3. Fentanyl
7.3.4. Ketamine
7.3.5. Methohexital Sodium
7.3.6. Propofol
7.3.7. Remifentanil
7.3.8. Others
8. US General Anesthesia Drugs Market, By End User (USD Million)
8.1. US General Anesthesia Drugs Market Value Share and Forecast, By End User, 2023-2033
8.2. Ambulatory Surgery Centres
8.3. Hospitals
9. US General Anesthesia Drugs Market Forecast, 2019-2033 (USD Million)
9.1. US General Anesthesia Drugs Market Size and Market Share
10. US General Anesthesia Drugs Market, By Route of Administration, 2019-2033 (USD Million)
10.1. US General Anesthesia Drugs Market Size and Market Share By Route of Administration (2019-2026)
10.2. US General Anesthesia Drugs Market Size and Market Share By Route of Administration (2027-2033)
11. US General Anesthesia Drugs Market, By End User, 2019-2033 (USD Million)
11.1. US General Anesthesia Drugs Market Size and Market Share By End User (2019-2026)
11.2. US General Anesthesia Drugs Market Size and Market Share By End User (2027-2033)
12. US General Anesthesia Drugs Market, By Region, 2019-2033 (USD Million)
12.1. US General Anesthesia Drugs Market Size and Market Share By Region (2019-2026)
12.2. US General Anesthesia Drugs Market Size and Market Share By Region (2027-2033)
12.3. Central Region
12.4. North Region
12.5. South Region
13. Company Profile
13.1. Abbott Laboratories
13.1.1. Company details
13.1.2. Financial outlook
13.1.3. Product summary
13.1.4. Recent developments
13.2. AbbVie
13.2.1. Company details
13.2.2. Financial outlook
13.2.3. Product summary
13.2.4. Recent developments
13.3. Akorn
13.3.1. Company details
13.3.2. Financial outlook
13.3.3. Product summary
13.3.4. Recent developments
13.4. AstraZeneca plc
13.4.1. Company details
13.4.2. Financial outlook
13.4.3. Product summary
13.4.4. Recent developments
13.5. Baxter International Inc.
13.5.1. Company details
13.5.2. Financial outlook
13.5.3. Product summary
13.5.4. Recent developments
13.6. Gilead Sciences, Inc
13.6.1. Company details
13.6.2. Financial outlook
13.6.3. Product summary
13.6.4. Recent developments
13.7. Heritage Pharmaceuticals Inc.
13.7.1. Company details
13.7.2. Financial outlook
13.7.3. Product summary
13.7.4. Recent developments
13.8. Novartis AG
13.8.1. Company details
13.8.2. Financial outlook
13.8.3. Product summary
13.8.4. Recent developments
13.9. Par Pharmaceutical
13.9.1. Company details
13.9.2. Financial outlook
13.9.3. Product summary
13.9.4. Recent developments
13.10. Pfizer Inc.
13.10.1. Company details
13.10.2. Financial outlook
13.10.3. Product summary
13.10.4. Recent developments
13.11. Others
14. List of Abbreviations
15. Reference Links
16. Conclusion
17. Research Scope

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us